Erica Gorman
Family · Blue Springs, MONPI 1184155236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 786 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 52 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,332, more than ten times the $524 reported in 2022. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 786 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$1K
- Pfizer$1K
- Regeneron Healthcare Solutions, Inc.$952
- Sanofi$919
- GSK$865
- plus $6K from 46 others
What the payments were for
- Food & beverage$13,999100%
- Education$680%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,067 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,639 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $910 |
| Omeprazole | 17 | $318 |
| Prednisone | 28 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $865 | $9,63911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Blue Springs
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.